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Introduction 
The important role of genetic factors in the pathogenesis of narcolepsy was realized very 
early in the course of research on this disease. One of the first recognized instances of 
narcolepsy, reported by Westphal in 1877 (1), was a familial case, as the mother of his patient 
suffered from the same disease. More than 100 years later, in 1984, the groups of Juji and 
Honda in Tokyo (2), and of Langdon and Parkes in London (3), found what could be the 
biochemical basis of hereditary factors in narcolepsy. Almost simultaneously they reported that 
all of their narcoleptic patients carry the HLA type DR2, while this antigen is present in only 
25—33% of the general population. 
Since then, immunogenetic methods have played a crucial role in narcolepsy research. As this 
field may not be familiar to those working in traditional areas of sleep research, this presenta-
tion will first give a short introduction, and then summarize some recent immunogenetic data 
which further outline the role of the HLA-system in the pathogenesis of narcolepsy. 
Basic Aspects of the HLA-System 
The Human Leukocyte Antigens (HLAs) are proteins which can be found on the surface of 
almost all human cells which contain a nucleus. Usually they are identified on leukocytes by 
serological methods, using specific antibodies. They first gained recognition in connection with 
transplantations, because they play an important role in the detection and rejection of foreign 
tissue by the immune system. HLA-identical transplants have a better graft survival than HLA-
incompatible ones. HLA-antigens are, as we know now, also involved in the mediation of many 
other immunological processes in the body. 
The structure of the HLA-antigens is genetically encoded on the short arm of chromosome 6 
in an area called the «major histocompatibility complex» or «HLA-region» (Fig. 1). In the 
HLA-region a large number of genes has been identified already, but there are still major 
sections with unknown functions. Besides the various HLA-genes there are also genes which 
encode complement factors and enzymes for Cortisol synthesis. The gene products of the HLA-
region are divided into three «classes» according to their structure and function (Fig. 2); class I 
contains the HLA-groups A, B, and C, which are involved in the cell mediated immune 
response. They are target structures for self-recognition by cytotoxic T-cells. Class III, which is 
located between classes I and II, comprises genes for complement factors and for Cortisol 
synthesis. The class II proteins are concerned with the immune response against soluble 
antigens. One of them is the DR antigen; neighboring ones are DQ and DP. The DR-region 
consists of several individual genes. They encode the two separate protein chains which 
together form the DR-molecule. The DRA is the gene for the alpha-chain, and shows little 
polymorphism. The DRB gene, which is present in several additional, usually inactive copies 
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Fig. 1: Location of the genes for HLA-antigens 
on the short arm of chromosome 6, in schematic 
magnification, a) Chromosome 6 during mitosis, 
b) Relative location of some important genes on 
the short arm of chromosome 6. HLA = HLA-
region («major histocompatibility complex»); 
PGM = phosphoglucomutase 3; GLO = glyoxal-
ase I; PG = pepsinogen; C6 = complement com-
ponent 6. c) HLA-region with gene-loci for HLA-
antigens A, B, C, DQ, DP, DR. 
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Fig. 2: Localization and function of genes in the HLA-region on chromosome 6: HLA A, B, C = Class I 
histocompatibility genes; HLA DN, DO, DP, DQ, DR - Class II histocompatibility genes. HLA-antigens 
usually consists of two separate protein chains, which are encoded by different genes; «A» denotes the 
gene for the alpha-chain, «B» the gene for the beta-chain (e.g., HLA-DRA = gene for alpha-chain of 
DR-antigen). «Bl» , «B2» etc.: multiple copies of the respective gene. C4 = complement component 4; 
C21-OH A = C21-hydroxylase A; C21-OH B = C21-hydroxylase B; Bf = Properdine-factor (B-factor); 
C2 = complement component 2; TNF — tumor necrosis factor. 
(DRB2, DRB3, etc.), encodes the beta-chain of the DR-molecule. This gene exists in multiple 
allelic versions which are responsible for the variability of the DR-molecules. 
As it may well be that it is the DR2-molecule itself, and not any neighboring gene, which is 
involved in the pathogenic process of narcolepsy, the function of this protein will be described 
in more detail. The DR-molecules, like other class II molecules, are primarily located on the 
surface of «accessory cells», which are mainly a type of macrophage. As mentioned above, the 
DR-molecule consists of two separate protein chains, alpha and beta, which are linked by 
noncovalent binding. Both chains are fixed in the cell membrane at one end (Fig. 3). On the far 
end of the molecule the proteins form a binding site for antigens. By X-ray cristallography the 
three-dimensional structure of this binding site has been analyzed; it has the form of a groove. 
The walls of this «groove» are formed by two protein alpha helices, with the bottom being 
made up of several parallel strings of the protein chains, looking somewhat like a gridiron. The 
variations between the HLA-DR types involve specific parts of the beta-chain in the section of 
the «walls», which results in a slightly different shape of the «groove». The function of the class 
II molecules is schematically shown in Fig. 4. In the process of recognition and binding of 
antigens, the class II molecules closely interact with the T-cell-receptor (TCR) in a stepwise 
reaction. The TCR is an immunoglobulin-like receptor on the surface of a T-lymphocyte, which 
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Fig. 3: Structure of class II molecule (e.g., HLA-
DR molecule). Two protein chains are fixed in the 
cell membrane of an accessory cell. Alpha and 
beta chain are linked by noncovalent binding. 
Allelic variability of HLA-DR types is due to vari-
ations of the protein sequence in the beta-1 loop. 




is highly specific for a certain antigen. The first step of this reaction is a non-specific binding of 
an antigen by the class II molecule. The binding strength to a certain antigen is determined by 
the form of the «groove», it varies according to the specific properties of a certain HLA-DR 
type. This binding is called «presenting» of the antigen. The «presenting» is a prerequisite for 
the next step, which is the binding of the TCR to its specific antigen. After this, the T-
lymphocyte reacts in its specific way by stimulating further steps of the immune response. 
For the DR-locus, now 16 allelic types have been identified, for other HLA-loci even more 
variants are known. They are expressed codominantly, so that the serologically defined FiLA 
phenotype of an individual is determined by the genes on both chromosomes 6. 
A statistical association with certain HLA types is known for a number of diseases. Most of 
them «run in families», like narcolepsy, but they do not show a clear Mendelian pattern of 
Fig. 4: Interaction of a class 11 
molecule and a T-cell-receptor 
(TCR) in the process of anti-
gen binding by a T-lympho-
cyte. The TCR can only bind 
to its specific antigen when it is 
presented by a class II 
molecule like HLA-DR or 
DQ. 
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transmission, such as, dominant or recessive. The strongest association next to narcolepsy is 
known for spondylitis ankylosans, Bechterew^ disease. About 90% of these patients carry the 
HLA B27, compared to 8 — 10% in the general population. Other examples are, in the order of 
decreasing strength of association, coelilac disease (DR3 + DR7), juvenile type of diabetes 
mellitus (DR3 + DR4), and multiple sclerosis, which is associated with DR2. 
HLA-Antigens and Narcolepsy 
Since 1984, a number of follow-up studies have been performed on the association between 
HLA DR2 and narcolepsy in different populations around the world, and there appear to be 
interesting differences depending on the racial background of the patients. In Japanese nar-
coleptics, representing the Oriental race, not a single DR2-negative case has been found among 
190 patients (4). In the Caucasian race DR2-negative patients are very rare, but they are found 
at a rate of 1—2% in various countries (5—7, see also 8). There is only one study which refers to 
a Negroid population. In 18 narcoleptic patients Neely et al. (9) found DR2 only in two thirds 
of the patients. Other authors also reported single cases of DR2-negative narcolepsy in Negroes 
(5,10). 
In a study which was performed in cooperation with the Neurological Clinic of the Charles 
University in Prague (11), we examined a total of 131 patients who suffer from narcolepsy, 
according to the criteria proposed by Honda (12). 129 of these patients carry the HLA DR2, 
and the other two do not. The results were confirmed by duplicate serological testing and by 
restriction fragment length polymorphisms (RFLP) analysis. The complete HLA types of the 
DR2-negative patients were All/- , B55/-, DR4/5, DRw52/53, DQw3/-, and A2/-, B60/61, 
DR1/5, DRw52/-, DQwl/3. Clinically, it was not possible to find any difference between the 
two DR2-negative patients and the others. In 6 of the patients, narcolepsy can be considered 
secondary to trauma or infection. All of them were DR2-positive, a finding which corresponds 
to the results of Matsuki et al. (4) who also found all of their patients with symptomatic 
narcolepsy to be DR2-positive. 
The standard method of HLA-typing is based on the reaction of living lymphocytes with 
defined antibodies. An alternative method, which in certain cases permits the detection of 
subtypes of serologically defined HLA types, is the analysis of RFLP. This technique shows 
genetic variations directly on the level of the DNA. In principle, the RFLP analysis is performed 
as follows: the DNA is extracted from the cell nuclei and digested by «restriction enzymes» 
which «cut» the DNA chain wherever a specific sequence of nucleotides occurs. The resulting 
«restriction fragments» are separated by electrophoresis and subsequently hybridized with a 
radioactively labeled probe which specifically binds to the gene under study. Finally, the 
fragments of the gene to which the probe was bound, are made visible by autoradiography. 
With this method, two subtypes (splits) of HLA DR2 can be distinguished, using the 
restriction enzyme Taq 1. These splits are now officially listed as DRwl5 and DRwl6. Similarly 
for HLA DQwl, which is strongly associated with DR1, DR2 and DRw6, the splits DQw5 and 
DQw6 were detected. DQw5 associates with DR1 and DRwlö, DQw6 goes with DRw6 and 
DRwlS. The DRwlS is much more frequent in the German population than DRwl6. In 118 
random controls, DRwl5 was present in 14%, DRwl6 in 0.9%. From our 129 DR2-positive 
narcoleptic patients, 128 were DRwl5/DQw6, one was DRwl6/DQw5. This is a very recent 
result and it will have to be followed up, especially regarding the single DRwl6 patient. The 
DR2-negative patient who was positive for DQwl carries the DQw5 split of this antigen. This 
result does not confirm the notion of some authors that the primary association of narcolepsy 
might not be with DR2 but rather with DQwl. In this case one would expect that the DR2-
negative narcoleptics carry DQw6, like the DR2-positive ones. 
Another interesting result of our study refers to the DR type on the second chromosome 6 of 
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our patients. From all published studies, it is obvious that the effect of DR2 is dominant, i. e., the 
frequency of DR2 on the second haplotype is not higher than statistically expected. The same 
result was found in our 131 patients, but there is another important difference in the distribu-
tion of the DR types compared to the controls. Only 7 out of 131 narcoleptic patients carry 
DRw6, corresponding to a gene frequency of 2.7%, while in the 118 controls the gene 
frequency of DRw6 was 18%. These values were confirmed by RFLP analysis. The difference is 
significant even after correction for the increased rate of DR2 in the patients. When reviewing 
the literature on this point, we found that many other authors had reported similar results in 
Caucasians, without further discussing this topic (4, 10, 13 —15, see Tab. 1). This rare occur-
rence of DRw6 in narcoleptic patients could indicate a certain protective effect of this gene 
against the hypothetical pathogenic agent which sets off narcolepsy. 
Tab. 1: Phenotype frequency of HLA-DRw6. 
Narcolepsy Controls 
Author Country Year n f(%) n f/2 (%) 
Matsuki et al. (4) Japan 1988 190 7.9** 310 9.6** 
Billiard et al. (13) France 1988 35 5.7 110 9.1* 
Lock et al. (10) U.K. 1988 60 8.3 60 11.7* 
Meier-Ewert et al. (15) W- Germany 1988 59 3.4 418 12.3* 
Montplaisir and Poirier (14) Canada 1988 48 2.1 150 11.7* 
Andreas-Zietz and Albert W-Germany and 
(unpublished results) Czechoslovakia 1988 131 2.7 118 9.0* 
Phenotype frequency of HLA-DRw6 in narcoleptic patients and controls. In the controls, the frequency 
value was divided by the factor 2 in order to correct for the almost 100% frequency of DR2 on the first 
haplotype of the narcoleptic patients, which lowers the a priori probability for other HLA-phenotypes. 
* significant difference between patients and controls (p < 0.01). 
* * combined values for D R w l 3 and DRwl4. 
Summarizing the results, the following points evolve: 
1. Narcolepsy is very highly associated with HLA DR2, but this association is, at least in 
Caucasian and Negroid populations, not equal to 100%. A common effort will be necessary to 
determine if the DR2-negative narcoleptic patients share certain features which distinguish 
them from the DR2-positive ones. 
2. With the available data, it cannot be decided whether the susceptibility gene for nar-
colepsy is the DR2 gene (DRB1) itself or a gene very closely linked to it. 
3. The very low frequency of HLA DRw6 in narcoleptic patients may be a hint that the 
second haplotype is also involved in the pathogenesis of narcolepsy. 
After all these immunogenetic considerations, we should not forget, however, that in the 
pathogenesis of narcolepsy non-genetic factors must be involved too. This is emphasized by 
recent reports on monozygotic twins who are clearly discordant for narcolepsy (16,17). 
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